Testimony Before the FDA’s Cardiovascular and Renal Drugs Advisory Committee Regarding Omecamtiv Mecarbil For the Treatment of Heart Failure

View complete testimony as PDF

View PowerPoint slides as PDF

In testimony before the Food and Drug Administration’s (FDA’s) Cardiovascular and Renal Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA not approve omecamtiv mecarbil to reduce the risk of cardiovascular death and heart failure events in adults with symptomatic chronic heart failure with reduced ejection fraction because the drug’s minimal benefits do not outweigh its significant risks.